ST. PETER, Minn. — Veterinary Pharmaceutical Solutions (VPS) announced its strategic expansion into poultry, including chickens and turkey, with new company research and personnel expansion.
Their expansion into poultry is marked by the appointment of a commercial director of poultry and the presentation of innovative research at the American Association of Avian Pathologists (AAAP) annual conference.
VPS named Darrell Stoner as its commercial director-poultry. In this new role, Stoner will increase engagement with poultry integrators and veterinarians to create new solutions in the poultry industry, the company noted.
He brings more than 20 years of experience to VPS after working in Elanco’s Poultry Division and serving as the former chair of the Health & Welfare Committee for the International Poultry Welfare Alliance. He has also served on the boards of The Poultry Federation and the National Turkey Federation.
At the AAAP, Dr. Brian Payne, VPS’ commercial R&D and technical service director, was chosen to present the company’s Meloxicam residue study in finishing-age turkeys. This study, which was conducted in collaboration with Iowa State University, supports informed withdrawal time recommendations for Meloxicam and ibuprofen, currently the only legally available water-soluble NSAIDs for use in poultry and livestock, the company added.
“VPS is well-known among swine veterinarians and producers for its high-quality compounded medications,” Stacy Peters, VPS chief commercial officer, said in a statement. “We’re excited to strengthen relationships with poultry veterinarians and integrators by continuing to deliver customized solutions that protect and improve flock health.”
